Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies
Conditions
Interventions
NP137
anti-PD-1/PD-L1
Locations
5
France
Centre Léon Bérard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Institut de Cancérologie Strasbourg Europe (ICANS)
Strasbourg, France
Institut Claudius Regaud (IUCT Oncopole)
Toulouse, France
Start Date
January 6, 2023
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
April 24, 2026
NCT07360314
NCT07403721
NCT07524348
NCT06898450
NCT05719558
NCT06248411
Lead Sponsor
Centre Leon Berard
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions